Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

NCT02042664 on ClinicalTrials.gov · last registry update 2026-05-07

A small phase 3 — 44 participants, against a typical 424. The sponsor logged completion for January 2015. Primary outcome, as filed: intracardiac triglyceride. exenatide is approved in the US, but not for diabetes and obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Assistance Publique Hopitaux De Marseille
Sponsor type: Other
Enrollment: 44
Started: 2011-01
Primary completion: 2015-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

intracardiac triglyceride

Conditions studied

Obesity · Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.